These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 33312386)
21. Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer. Zhu K; Deng W; Deng H; Liu X; Wang G; Fu B PPAR Res; 2021; 2021():7056506. PubMed ID: 35027921 [TBL] [Abstract][Full Text] [Related]
22. Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma. Liu Y; Jian J; Zhang Y; Wang L; Liu X; Chen Z Front Oncol; 2023; 13():1170893. PubMed ID: 37124542 [TBL] [Abstract][Full Text] [Related]
23. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation. Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P Front Immunol; 2023; 14():955949. PubMed ID: 37006317 [TBL] [Abstract][Full Text] [Related]
24. A gene signature of cancer-associated fibroblasts predicts prognosis and treatment response in bladder cancer. Chen X; Liao C; Zou X; Zhang B; Mo Z Clin Transl Oncol; 2024 Feb; 26(2):477-495. PubMed ID: 37594617 [TBL] [Abstract][Full Text] [Related]
25. Identification and Development of Inflammatory Response-Related Genes Signature Associated With Prognosis Evaluation and Immune Status of Bladder Cancer. Zheng H; Luo W; Li Y; Peng G; Zhou D; Tang D; Cheng J; Wu S Front Cell Dev Biol; 2022; 10():837849. PubMed ID: 35309900 [No Abstract] [Full Text] [Related]
26. Preclinical analysis of novel prognostic transcription factors and immune-related gene signatures for bladder cancer via TCGA-based bioinformatic analysis. Deng Y; Hong X; Yu C; Li H; Wang Q; Zhang Y; Wang T; Wang X Oncol Lett; 2021 May; 21(5):344. PubMed ID: 33747201 [TBL] [Abstract][Full Text] [Related]
27. High expression of Lin B; Zhang T; Ye X; Yang H Oncol Lett; 2020 Sep; 20(3):2840-2854. PubMed ID: 32782602 [TBL] [Abstract][Full Text] [Related]
28. Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism-related genes and their relationships with immune infiltration. Huang C; Li Y; Ling Q; Wei C; Fang B; Mao X; Yang R; Zhang L; Huang S; Cheng J; Liao N; Wang F; Mo L; Mo Z; Li L FEBS Open Bio; 2023 Apr; 13(4):736-750. PubMed ID: 36814419 [TBL] [Abstract][Full Text] [Related]
29. A Multiomics Profiling Based on Online Database Revealed Prognostic Biomarkers of BLCA. Li H; Chen S; Mi H Biomed Res Int; 2022; 2022():2449449. PubMed ID: 35669725 [TBL] [Abstract][Full Text] [Related]
30. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma. Mi Y; Wang X J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952 [TBL] [Abstract][Full Text] [Related]
31. The Construction and Analysis of Tumor-Infiltrating Immune Cells and ceRNA Networks in Bladder Cancer. Jiang A; Liu N; Bai S; Wang J; Gao H; Zheng X; Fu X; Ren M; Zhang X; Tian T; Ruan Z; Yao Y; Liang X Front Genet; 2020; 11():605767. PubMed ID: 33391354 [TBL] [Abstract][Full Text] [Related]
32. Construction and evaluation of a novel prognostic risk model of aging-related genes in bladder cancer. Wang D; Ning H; Wu H; Song Y; Chu Y; Liu F; Zhao Z; Wu F; Lyu J Curr Urol; 2023 Dec; 17(4):236-245. PubMed ID: 37994343 [TBL] [Abstract][Full Text] [Related]
33. TNF Family-Based Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma. Li H; Liu S; Li C; Xiao Z; Hu J; Zhao C Front Cell Dev Biol; 2021; 9():800967. PubMed ID: 35174161 [No Abstract] [Full Text] [Related]
34. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases. He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970 [TBL] [Abstract][Full Text] [Related]
35. Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer. Zhang LH; Li LQ; Zhan YH; Zhu ZW; Zhang XP Front Mol Biosci; 2021; 8():607090. PubMed ID: 33937319 [TBL] [Abstract][Full Text] [Related]
36. A Prognostic Model for Predicting Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Bladder Urothelial Carcinoma. Wang C; Chen S; Li S; Mi H Front Genet; 2022; 13():708003. PubMed ID: 35251120 [TBL] [Abstract][Full Text] [Related]
37. Bioinformatics Analysis Finds Immune Gene Markers Related to the Prognosis of Bladder Cancer. Chen X; Jin Y; Gong L; He D; Cheng Y; Xiao M; Zhu Y; Wang Z; Cao K Front Genet; 2020; 11():607. PubMed ID: 32655621 [TBL] [Abstract][Full Text] [Related]
38. Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma. Zuo Z; Xiong J; Zeng C; Jiang Y; Xiong K; Tao H; Guo Y Front Mol Biosci; 2021; 8():625470. PubMed ID: 33748188 [No Abstract] [Full Text] [Related]
39. Exploring the Molecular Mechanisms and Shared Gene Signatures Between Systemic Lupus Erythematosus and Bladder Urothelial Carcinoma. Wang K; Wang S; Ding Y; Kou Z; Jiang B; Hou S Int J Gen Med; 2024; 17():705-723. PubMed ID: 38435117 [TBL] [Abstract][Full Text] [Related]
40. Development and Validation of Prognostic Model in Transitional Bladder Cancer Based on Inflammatory Response-Associated Genes. Xie Z; Cai J; Sun W; Hua S; Wang X; Li A; Jiang J Front Oncol; 2021; 11():740985. PubMed ID: 34692520 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]